ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,901 to 3,920 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
CT Coronary Angiogram vs Standard Care: serious adverse events18 of 877

10 of 871

0.9 points

-0.3 to 2.2

1,748NCT02284191

Rapid Assessment of Potential Ischaemic Heart Disease With CTCA

Vadadustat vs Darbepoetin Alfa: deaths from any cause180 of 878

168 of 870

1.2 points

-2.6 to 4.9

1,748NCT02648347

Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease

Vadadustat vs Darbepoetin Alfa: serious adverse events573 of 878

561 of 870

0.8 points

-3.7 to 5.2

1,748NCT02648347

Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease

Arm I (Zoledronic Acid Every 4 Weeks) vs Arm II (Zoledronic Acid Every 12 Weeks): deaths from any cause41 of 879

42 of 868

-0.2 points

-2.2 to 1.9

1,747NCT00869206

Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

Arm I (Zoledronic Acid Every 4 Weeks) vs Arm II (Zoledronic Acid Every 12 Weeks): serious adverse events96 of 879

103 of 868

-0.9 points

-3.9 to 2.0

1,747NCT00869206

Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

Creatine vs Placebo: serious adverse events315 of 874

347 of 867

-4.0 points

-8.5 to 0.6

1,741NCT00449865

NET-PD LS-1 Creatine in Parkinson's Disease

CABG vs PCI With DES: Repeat Revascularization (PCI and/or CABG).50 of 849

120 of 891

-7.6 points

-10.4 to -4.8

1,740NCT00114972

SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries

CABG vs PCI With DES: Primary Clinical Endpoint of 12-Month Binary MACCE.105 of 849

159 of 891

-5.5 points

-8.8 to -2.1

1,740NCT00114972

SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries

CABG vs PCI With DES: 12-month Composite Safety Endpoint.65 of 849

68 of 891

0.0 points

-2.5 to 2.6

1,740NCT00114972

SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries

Semaglutide vs Insulin Aspart: deaths from any cause12 of 874

1 of 864

1.3 points

0.5 to 2.3

1,738NCT03689374

A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes

Semaglutide vs Insulin Aspart: serious adverse events65 of 874

84 of 864

-2.3 points

-4.9 to 0.4

1,738NCT03689374

A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes

BG00012 240 mg BID vs BG00012 240 mg TID: Number of Participants With Treatment-Emergent Adverse Events (AEs)824 of 868

814 of 868

1.2 points

-1.0 to 3.4

1,736NCT00835770

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)

BG00012 240 mg BID vs BG00012 240 mg TID: deaths from any cause5 of 868

6 of 868

-0.1 points

-1.0 to 0.7

1,736NCT00835770

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)

BG00012 240 mg BID vs BG00012 240 mg TID: serious adverse events279 of 868

272 of 868

0.8 points

-3.6 to 5.2

1,736NCT00835770

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)

INV_MMR vs COM_MMR: Number of Subjects Reporting Any Serious Adverse Events (SAEs)24 of 1,164

9 of 572

0.5 points

-1.1 to 1.7

1,736NCT02184572

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

INV_MMR Group vs COM_MMR Group: Number of Subjects Reporting Any Unsolicited AEs598 of 1,164

277 of 572

2.9 points

-2.1 to 7.9

1,736NCT02184572

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

INV_MMR Group vs COM_MMR Group: serious adverse events24 of 1,164

9 of 572

0.5 points

-1.1 to 1.7

1,736NCT02184572

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

Umbilical Cord Milking - Neonates vs Early Cord Clamping - Neonates: Number of Neonatal Deaths0 of 872

4 of 858

-0.5 points

-1.2 to 0.1

1,730NCT03631940

Umbilical Cord Milking in Non-Vigorous Infants

Umbilical Cord Milking-Neonates vs Early Cord Clamping-Neonates: deaths from any cause0 of 872

4 of 858

-0.5 points

-1.2 to 0.1

1,730NCT03631940

Umbilical Cord Milking in Non-Vigorous Infants

Umbilical Cord Milking-Neonates vs Early Cord Clamping-Neonates: serious adverse events1 of 872

2 of 858

-0.1 points

-0.7 to 0.4

1,730NCT03631940

Umbilical Cord Milking in Non-Vigorous Infants

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=196"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=196

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02284191-sae",
        "title": "CT Coronary Angiogram vs Standard Care: serious adverse events",
        "summary": "18 of 877 against 10 of 871; risk difference 0.9 points, 95% interval -0.3 to 2.2; NCT02284191, Rapid Assessment of Potential Ischaemic Heart Disease With CTCA",
        "record": "/library/comparisons/NCT02284191-sae",
        "nct_id": "NCT02284191",
        "kind": "serious-adverse-events",
        "participants": 1748,
        "risk_difference": {
          "value": 0.009043459136210885,
          "lower": -0.003080320083924594,
          "upper": 0.021846789965071407
        },
        "group_1": "18 of 877",
        "group_2": "10 of 871",
        "difference": "0.9 points",
        "interval": "-0.3 to 2.2",
        "trial_title": "Rapid Assessment of Potential Ischaemic Heart Disease With CTCA"
      },
      {
        "id": "NCT02648347-deaths",
        "title": "Vadadustat vs Darbepoetin Alfa: deaths from any cause",
        "summary": "180 of 878 against 168 of 870; risk difference 1.2 points, 95% interval -2.6 to 4.9; NCT02648347, Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease",
        "record": "/library/comparisons/NCT02648347-deaths",
        "nct_id": "NCT02648347",
        "kind": "deaths",
        "participants": 1748,
        "risk_difference": {
          "value": 0.011907941245778014,
          "lower": -0.025562625627787633,
          "upper": 0.04932099987997881
        },
        "group_1": "180 of 878",
        "group_2": "168 of 870",
        "difference": "1.2 points",
        "interval": "-2.6 to 4.9",
        "trial_title": "Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=197",
  "request_id": "J4Hxs7n2A6tB4uW8"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?